iNtRON signs licence deal with Basilea for antibacterial bio-drug SAL200
iNtRON Biotechnology has signed an “evaluation licence and option agreement” with Basilea Pharmaceutica, which grants Basilea the option to enter into an exclusive licence agreement for the antibacterial